|Bid||53.19 x 1100|
|Ask||90.00 x 1300|
|Day's Range||74.21 - 76.94|
|52 Week Range||34.04 - 80.44|
|Beta (5Y Monthly)||1.04|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 26, 2021 - Jul 30, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||88.00|
MASON, Ohio, Jun 15, 2021--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Deborah H. Telman and Maggie Yuen have been elected to its Board of Directors.
AtriCure, Inc. ( NASDAQ:ATRC ) has exhibited strong share price growth in the past few years. However, its earnings...
AtriCure (ATRC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.